Stefan Samuelson, MD
Anesthesiology · New York, NYNPI 1174787477
Payments from drug & device makers
Across 119 payments — averaging $47.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$2K
- AbbVie$1K
- BD$600
- Teva Pharmaceuticals USA, Inc.$288
- Pfizer$275
- Nevro Corp.$261
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$60011%
- Food & beverage$5,01589%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 1 | $1,687 |
| AbbVie(2 entities) | 47 | $1,077 |
| BD | 1 | $600 |
| Teva Pharmaceuticals USA, Inc. | 11 | $288 |
| Pfizer | 14 | $275 |
| Nevro Corp. | 2 | $261 |
| Biodelivery Sciences International, Inc. | 7 | $246 |
| Lundbeck LLC | 7 | $238 |
| Collegium Pharmaceutical, Inc. | 10 | $190 |
| Medtronic(2 entities) | 3 | $184 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $140 |
| Merz Pharmaceuticals, LLC | 4 | $132 |
| Amgen | 1 | $119 |
| Novartis | 4 | $71 |
| Biohaven Pharmaceuticals, Inc. | 2 | $46 |
| Fidia Pharma USA Inc. | 1 | $29 |
| IBSA Pharma Inc. | 1 | $21 |
| SPR Therapeutics, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,615 in reported general payments places this provider in the 95th percentile of 4,157 anesthesiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 21 | $52,789 |
| PercocetOxycodone Hcl/Acetaminophen | 13 | $52,099 |
| BotoxOnabotulinumtoxina | 11 | $14,151 |
| BelbucaBuprenorphine Hcl | 20 | $12,513 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $12,099 |
| OxycontinOxycodone Hcl | 24 | $11,245 |
| Oxycodone Hcl | 196 | $5,038 |
| Fentanyl | 11 | $3,072 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $2,865 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 94 | $2,587 |
| Lidocaine | 11 | $2,471 |
| Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol | 19 | $2,363 |
| Morphine Sulfate ErMorphine Sulfate | 87 | $2,246 |
| Pregabalin | 79 | $2,163 |
| Gabapentin | 107 | $1,241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $140 | $52,78921 claims |
| AbbVieBotox | $1,077 | $14,15111 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $190 | $12,51320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,157 anesthesiology providers in New York.
Other anesthesiology in New York
- Kiran PatelNew York$832K
- Marc DicksteinNew York$585K
- Daniel KatzNew York$531K
- Admir HadzicNew York$510K
- Christopher DimeoNew York$449K
- Zachary TurnbullNew York$435K
- Christopher RieglerNew York$429K
- William UrmeyNew York$397K
- Sudhir DiwanNew York$255K
- Richard SmileyNew York$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.